The Swiss Parliament has rejected a motion to allow the use of cannabis in scientific studies investigating the drug's effects.
Opponents of the rejected motion saw it as a back-door path towards liberalization, the Xinhua quoted the Swiss media as reporting on Tuesday.
After a narrow victory at the committee stage, the motion was rejected on Monday in the House of Representatives by another slim margin: 96 votes to 93, with two abstentions, the Swiss News Agency, SDA-ATS, reported.
The conservative-right Swiss People's Party and centrist Christian Democrats voted against the idea, which they saw as an implicit route towards liberalizing cannabis consumption.
Supporters of the project, which aimed to make cannabis available for academic studies about the effects of prescribed versions of the drug, had claimed that it would allow for a better understanding of possible health and social problems.
The vote came after a November 2017 federal decision to block a University of Bern study that was requested by the city's authorities into possible effects of the regulated sale of cannabis in pharmacies.
At the time, the Federal Office of Public Health, despite not rejecting the project in principle, said the request could not be granted.
It said: "Current drugs legislation does not allow the use of cannabis for non-medical reasons ... for such a study to be permitted, the law would have to be supplemented by a special legal provision for scientific pilot projects."
The Parliament's decision thus eliminated the possibility, for now, of such a legal provision being enacted.
Growing, consuming and dealing cannabis are all forbidden in Switzerland.
--IANS
tsb
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
